Navigation Links
Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Date:5/20/2008

NEW YORK, May 20 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced that Richard Taney, President and Chief Executive Officer, provided an update on enrollment numbers in the Company's pivotal Phase III clinical trial today at a gathering of financial and healthcare industry leaders attending the Rodman & Renshaw 5th Annual Global Healthcare Conference.

Mr. Taney's comments updated patient recruitment levels for the Phase III clinical trial of the Company's Percutaneous Hepatic Perfusion (PHP) technology for inoperable cancers in the liver. Enrollment in this pivotal trial, which is treating patients with metastatic melanoma, now totals 32 patients which surpasses one-third of the 92 patients required to complete enrollment of the trial. This represents an acceleration in patient enrollment in this NCI-led multi center trial, and occurs before accrual has begun at the first additional trial site which is the University of Maryland Medical Center.

Although the company is prevented from commenting on results from the randomized Phase III trial, Mr. Taney was able to update the audience on the parallel Phase II trial for patients with metastatic melanoma in the liver who had previously received surgical isolated regional therapy and are therefore ineligible for admission to the pivotal Phase III study. All five of the patients treated in this arm to date have shown responses to PHP and four of the five (80%) have shown objective tumor responses of 30% or greater reduction in tumor size.

Mr. Taney also discussed the metastatic neuroendocrine arm of Delcath's ongoing Phase II trial. This study was the subject of a well-attended presentation during the American Hepato Pancreato Biliary Association Annual Meeting in March of this year. At that meeting, NCI investigators reported a 79% overall response rate in the 23 evaluable patients, including two complete responses. In addition to reporting an unprecedented rate of response in this patient group, the median hepatic progression free survival was reported to be 39 months.

The presentation was webcast live and will be available for ninety days and accessible at http://www.delcath.com .

About Delcath Systems, Inc.

Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested in Phase III and Phase II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver, including melanomas, neuroendocrine tumors and adenocarcinomas. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at http://www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
4. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
5. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
6. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
7. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
8. BioCryst Updates Peramivir Clinical Development Plan
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
11. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 23, 2017  The particle counters market is ... from USD 275.9 million in 2016, at a ... report: http://www.reportlinker.com/p04718602-summary/view-report.html The growing ... R&D, and growth in manufacturing industries in emerging ... for particle counters. On the other hand, technical ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans ... important that we all are aware of our options and are empowered with ... announce the launch of its newest edition of "Vision and Hearing" in USA ...
(Date:2/24/2017)... Viejo, CA (PRWEB) , ... February 24, 2017 , ... ... Final Cut Pro X . Users have total control over position, rotation, distortion, ... and more all within Final Cut Pro X. , With ProGlass Prism users are ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) ... You See” body image mannequin art competition. Selected from 15 submissions from around the ... revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... services, which specializes in thought leadership , media relations, social media, content ... services that will be powered through Act-On, an intuitive marketing automation platform. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
Breaking Medicine News(10 mins):